Upcoming events

Pharming to host Virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET).

The Investor Day agenda will include a comprehensive update on our advancing pipeline, including leniolisib in Phase II proof of concept clinical trials for primary immunodeficiencies (PIDs) with immune dysregulation, including Common Variable Immunodeficiency (CVID) with immune dysregulation, as well as KL1333 in a pivotal clinical study (FALCON) for mitochondrial DNA (mtDNA)-driven mitochondrial disease. We will also present our 2026 financial guidance, highlighting anticipated revenue drivers and operating expense expectations.

Additional details for the Investor Day, including registration information, will be made available on our website in the coming weeks.

Pharming to report 4Q/FY 2025 financial results on March 12, 2026, at 07:00 CET. You can find other results on our Financial Documents page.

The Annual Report 2025 will be released on April 2, 2026.

Pharming to report 1Q 2026 financial results on May 7, 2026, at 07:00 CET. You can find other results on our Financial Documents page.

Pharming to report 2Q/1H 2026 financial results on July 30, 2026, at 07:00 CET. You can find other results on our Financial Documents page.

Pharming to report 3Q 2026 financial results on November 5, 2026, at 07:00 CET. You can find other results on our Financial Documents page.